Cefpirome
Systematic (IUPAC) name | |
---|---|
1-{[(6R,7R)-7-[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-2-carboxylato-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl}-5H,6H,7H-cyclopenta[b]pyridin-1-ium | |
Clinical data | |
AHFS/Drugs.com | International Drug Names |
Identifiers | |
CAS Number | 84957-29-9 |
ATC code | J01DE02 (WHO) |
PubChem | CID 6917674 |
ChemSpider | 23089536 |
UNII | S72Q2F09HY |
KEGG | D07649 |
ChEMBL | CHEMBL2106076 |
Chemical data | |
Formula | C22H22N6O5S2 |
Molar mass | 514.58 g/mol |
| |
| |
(what is this?) (verify) |
Cefpirome is a fourth-generation cephalosporin. Trade names include Cefrom, Keiten, Broact, and Cefir. Cefpirome is considered highly active against Gram-negative bacteria, including Pseudomonas aeruginosa, and Gram-positive bacteria.
Spectrum of bacterial susceptibility and resistance
Bacteroides fragilis, enterococci, Pseudomonas spp. and staphylococci are resistant to cefpirome sulfate, and some Haemophilus spp. and pneumococci have developed resistance to it to varying degrees.[1]
References
- ↑ "Cefpirome Sulfate spectrum of bacterial susceptibility and Resistance" (PDF). Retrieved 10 April 2012.
|
This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.